CLEC10A and malignant colon neoplasm: In summary, our results indicate that MGL ligand expression is a prognostic biomarker in stage III colon cancer patients, irrespective of MSI status or adjuvant chemotherapy consistent with the putative immunosuppressive effects of aberrant glycosylation.